Both studies used Truveta’s de-identified electronic health record (EHR) data to examine outcomes that are difficult to study in randomized trials alone, spanning heart failure, GLP-1-based cardiometabolic therapy, and advanced kidney disease.
Study snapshot: Heart failure outcomes with GLP-1 RA treatment and discontinuation
This real-world retrospective cohort study examined one-year heart failure outcomes among adults with overweight or obesity treated with GLP-1 receptor agonists (GLP-1 RAs), including injectable semaglutide and tirzepatide.
Using Truveta Data, investigators identified 289,809 adults who initiated GLP-1 RA therapy between July 2022 and December 2024 and compared outcomes between patients who discontinued treatment within one year and those who continued therapy for at least one year. Outcomes were assessed both during treatment and after discontinuation.
Key findings
- Early discontinuation (<1 year) was associated with higher one-year risks of all-cause mortality, acute heart failure events, and heart failure–related hospitalizations during treatment.
- Discontinuation was common in real-world care, with nearly 30% of patients stopping therapy within one year.
- After treatment discontinuation, overall event rates increased, with similar post-discontinuation risks regardless of prior treatment duration.
These findings provide real-world context around GLP-1 RA persistence and heart failure outcomes, highlighting how treatment patterns observed in routine care may influence cardiovascular risk.
Study snapshot: Incident heart failure and progression to end-stage kidney disease
The second study focused on patients with advanced chronic kidney disease (CKD) and no prior history of heart failure, examining how incident heart failure affects progression to end-stage kidney disease (ESKD) and mortality.
investigators followed 10,901 adults with advanced CKD between January 1, 2023 and December 31, 2024.
Key findings
- Early discontinuation (<1 year) was associated with higher one-year risks of all-cause mortality, acute heart failure events, and heart failure–related hospitalizations during treatment.
- Discontinuation was common in real-world care, with nearly 30% of patients stopping therapy within one year.
- After treatment discontinuation, overall event rates increased, with similar post-discontinuation risks regardless of prior treatment duration.
These findings provide real-world context around GLP-1 RA persistence and heart failure outcomes, highlighting how treatment patterns observed in routine care may influence cardiovascular risk.
Why it matters
While the two studies address different clinical questions, they share common themes. Both focus on patients at elevated cardiovascular risk, rely on longitudinal follow-up across large and diverse populations, and examine treatment patterns as they occur in real-world clinical care. Together, they demonstrate how real-world data can support rigorous cardiovascular research across complex patient trajectories.
